Skip to content

A randomised controlled two part study to evaluate the effectiveness of different education methods to achieve serum phosphate levels set by the Renal Association for haemodialysis patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN38137821
Enrollment
68
Registered
2003-09-12
Start date
2002-11-04
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases: Haemodialysis Urological and Genital Diseases Haemodialysis

Interventions

68 patients will be recruited and randomised into 4 groups. Baseline data on their phosphate knowledge and routine blood chemistry will be obtained. Two groups will attend group education sessions run

Sponsors

Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients will be recruited from Barts and The London NHS Trust haemodialysis population. This includes hospital and satellite units. Inclusion criteria: 1. Serum phosphate: >1.7 mmol/l 2. Serum calcium: 2.2 - 2.6 mmol/l 3. Serum parathyroid hormone (PTH): 10-50 pmol.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Group 1 (both interventions): results for phosphate knowledge and serum phosphate control should be the best out of all the groups Groups 2 + 3 (each had one intervention only, group teaching session and intensive clinic respectively): results for phosphate knowledge and serum phosphate control should improve versus baseline Group 4 (control): results for phosphate knowledge and serum phosphate control should be similar to baseline

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026